According to the recent statistical data, ovarian cancer is responsible for the death of over 150,000+ women worldwide each year and kills more women than all other gynecologic cancers combined. Also, it must be stressed that ovarian cancer is the second deadliest cancer for women and the fifth leading cause of cancer death in women. Symptomatology is usually complex, nonspecific and sometimes misleading, and the diagnosis of the disease in itsâ early stage is in approximately 20% of patients. 5-year survival rate is different, and ranges from 90% in early stage ovarian cancer patients up to 11% in the advanced stages of the disease.
In order to make a proper diagnosis in itsâ early stage and better patient care, numerous investigations were performed and several serum ovarian cancer biomarkers identified.
In spite of all these efforts, up to now there is no adequate screening test for ovarian cancer. Therefore, the identification of oncology biomarkers for screening and monitoring of occult tumors has been highly prioritized. In routine clinical practice assessment for early detection of ovarian cancer can be achieved using tumor markers such as CEA, Ca 19-9, Ca 15-3 combined with Ca-125 and HE4 levels. Other tumor markers (such as CA72-4, OVX1, Inhibin, beta-hCG, AFP, M-CSF etc.) should be respected for early detection of ovarian cancer, but not used in everydaysâ approach. In conclusion, blood levels of tumor markers can be good predictors of the adnexal masses nature. But still, for the most precise preoperative prognosis of adnexal tumors nature the combination of tumor markers should be used. Serum Tumor Markers Evaluation in Patients with Adnexal Masses â Current Value in Everydays Clinical Practice, Milan Terzic and Jelena Dotlic.
Last date updated on February, 2021